Christopher Ghadban

Lyric Bio, Inc. is on a mission to reshape the global supply of life-saving medicines with its next-generation biomanufacturing platform. Every year, thousands of patients with immune deficiencies and neurological disorders rely on intravenous immunoglobulin (IvIg), but supply remains critically limited—often falling short of growing needs. The global IvIg market is already valued at over $20 billion and is projected to see strong growth as both diagnosis rates and clinical indications rise. Yet, traditional plasma-derived processes cannot keep pace, leaving patients and clinicians facing persistent shortages. Lyric Bio stands at the forefront of this market opportunity, unlocking scalable, efficient production technology to break through the bottlenecks that have long constrained access. For patients, Lyric Bio’s innovation means hope—offering the promise of consistent, reliable access to high-quality therapies. By reimagining how essential biologics like IvIg are made, Lyric Bio is delivering groundbreaking technology that will enable first in vitro production other donor derived complex therapeutics such as stem cells and red blood cells.

TVC is a transformational, early-stage venture firm backed by world class entrepreneurs and business leaders. Led by a seasoned team of venture investors, ex-founders, and investment management executives, we invest our capital, time, and network into highly defensible, fast-growing companies with the potential to solve the world’s largest problems. Our strategy is grounded on writing high conviction checks at Pre-Seed and Seed with healthy follow-on reserves through Series A; demonstrating deep value to enable increased ownership over time. Our experienced team is headquartered in New York City and London, but we are excited to meet founders from around the world with a strong preference for diverse founding teams. At its core, we believe that diversity is not only good for business, but great for financial returns.

Supercharging immunotherapy

InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.

Unlocking the potential of macrocycle drug discovery through machine learning and massively parallel synthesis

Coding Bio is building next-gen multi-specific T-cell engagers for the most challenging to treat indications in oncology and beyond

Lyric Bio, Inc. is on a mission to reshape the global supply of life-saving medicines with its next-generation biomanufacturing platform. Every year, thousands of patients with immune deficiencies and neurological disorders rely on intravenous immunoglobulin (IvIg), but supply remains critically limited—often falling short of growing needs. The global IvIg market is already valued at over $20 billion and is projected to see strong growth as both diagnosis rates and clinical indications rise. Yet, traditional plasma-derived processes cannot keep pace, leaving patients and clinicians facing persistent shortages. Lyric Bio stands at the forefront of this market opportunity, unlocking scalable, efficient production technology to break through the bottlenecks that have long constrained access. For patients, Lyric Bio’s innovation means hope—offering the promise of consistent, reliable access to high-quality therapies. By reimagining how essential biologics like IvIg are made, Lyric Bio is delivering groundbreaking technology that will enable first in vitro production other donor derived complex therapeutics such as stem cells and red blood cells.

TVC is a transformational, early-stage venture firm backed by world class entrepreneurs and business leaders. Led by a seasoned team of venture investors, ex-founders, and investment management executives, we invest our capital, time, and network into highly defensible, fast-growing companies with the potential to solve the world’s largest problems. Our strategy is grounded on writing high conviction checks at Pre-Seed and Seed with healthy follow-on reserves through Series A; demonstrating deep value to enable increased ownership over time. Our experienced team is headquartered in New York City and London, but we are excited to meet founders from around the world with a strong preference for diverse founding teams. At its core, we believe that diversity is not only good for business, but great for financial returns.

Supercharging immunotherapy

InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.